InnoPharmaScreen Inc.(IPS), Hoseo University in Korea Republic was established in 2007 for new drug discovery and protein expression profiling for development of new biomarkers. 

IPS offers an innovative approach for a novel drug discovery by using an Integrated Drug Discovery Platform (IDDP) that involves 'structure-based in silico drug design', 'Protein Chip- based high performance screening', 'Cell based-Bioassay' including in vitro AMDE/Tox assay, and lead optimization. 

IPS's IDDP, an unique drug discovery system, can rapidly, economically screen new lead materials and druggable candidates. IPS provides the high quality service for new drug discovery using IDDP to drug pharma and biotech companies, which want to find out a novel drug for a selected target. 

IPS has already validated the IDDP technology dealing with a number of biologically relevant targets including disease-related enzymes such as kinases and protease, cell adhesion molecule such as integrin, beta amyloid peptide, and other protein-protein interactions for different therapeutic applications including cancer, Angiogenesis, Diabetes, osteoporosis, Alzheimer, and inflammatory diseases. 

In these therapeutic areas, IPS is building up a pipeline of programs for early partnering with Pharmaceutical and Biotechnology companies.